Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
BMC Medicine|December 2, 2014
Clinical considerations and key issues in the management of patients with Erdheim-Chester Disease: a seven case seriesRoei D Mazor, Mirra Manevich-Mazor, Anat Kesler, et al.
American Journal of Hematology|April 1, 2018
Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: An observational multi-center retrospective studyYael C Cohen, Avi Saranga, Moshe E Gatt, et al.
Genes, Chromosomes & Cancer|May 7, 2016
Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?Merav Leiba, Adrian Duek, Ninette Amariglio, et al.
British Journal of Haematology|November 17, 2015
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational studyEli Muchtar, Moshe E Gatt, Ory Rouvio, et al.
Annals of Hematology|June 23, 2022
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysisShai Shimony, Jonathan Canaani, Eitan Kugler, et al.
European Journal of Haematology|September 19, 2020
Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remissionYishai Ofran, Ronit Leiba, Avraham Frisch, et al.
European Journal of Haematology|May 31, 2023
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemiaJonathan Canaani, Avraham Frisch, Daniel A Pollyea, et al.
American Journal of Hematology|April 9, 2021
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practiceArie Apel, Yakir Moshe, Yishai Ofran, et al.
Blood Advances|October 1, 2021
CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trialsChezi Ganzel, Ju-Whei Lee, Hugo F Fernandez, et al.
Leukemia Research|March 5, 2018
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcomeChezi Ganzel, Ory Rouvio, Irit Avivi, et al.
Pageof 5